English Court to consider Premaitha’s defence after hearing scheduled for July 2017
AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. As explained by AstraZeneca, Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.
Allergan and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation have entered into an agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.
As the medical market grows, the US Food and Drug Administration FDA has published a neat piece about biosimilars. Recently, FDA has approved a second biosimilar product—Inflectra (Infliximab-dyyb), a biosimilar to Remicade (infliximab)—and expects to approve other biosimilars in the future.
Primary Health Properties PLC, a UK-based investor in modern primary healthcare facilities, has appointed Geraldine Kennell and Nick Wiles to the Board as independent non-executive Directors.
TALTZ was recently approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.
The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate “inversions,” with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.